Opioid Induced Constipation News and Research

RSS
Opioid maker funds efforts to fight addiction: Is it ‘blood money’ or charity?

Opioid maker funds efforts to fight addiction: Is it ‘blood money’ or charity?

Naldemedine significantly improves opioid-induced constipation in patients with chronic non-cancer pain

Naldemedine significantly improves opioid-induced constipation in patients with chronic non-cancer pain

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Once-a-day pill for patients experiencing opioid-induced constipation

Once-a-day pill for patients experiencing opioid-induced constipation

Naloxegol holds hope for opioid-induced constipation

Naloxegol holds hope for opioid-induced constipation

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo's supplemental new drug application for AMITIZA gets FDA approval